Hepatitis c virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 2, 2010, Pages 190-199

  Ogasawara, Ken ^a   Terada, Tomohiro ^a   Toshiya, Katsura ^a   Hatano, Etsuro ^b   Ikai, Iwao ^b   Yamaoka, Yoshio ^c   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Kitano Hospital   (Japan)

Author keywords

Cirrhosis; HCV; Liver; mRNA expression; MRP4; Multiple regression; Transporter

Indexed keywords

ABC TRANSPORTER; CARRIER PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 6; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 2B1; ORGANIC CATION TRANSPORTER 1; UNCLASSIFIED DRUG;

ACCURACY; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; TISSUE SECTION;

EID: 77952590222     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.190     Document Type: Article

References (47)

1. Faber, K. N., Muller, M. and Jansen, P. L.: Drug transport proteins in the liver. Adv. Drug Deliv. Rev., 55: 107-124 (2003).
2. Chandra, P. and Brouwer, K. L.: The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res., 21: 719-735 (2004).
3. Jonker, J. W. and Schinkel A. H.: Pharmacological and physiological functions of the olyspecific organic cation transporters:OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther., 308:2-9 (2004).
4. Anzai, N., Kanai, Y. and Endou, H.: Organic anion transporter family: current knowledge. J. Pharmacol. Sci., 100: 411-426 (2006).
5. Hagenbuch, B. and Meier, P. J.: Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflügers. Arch., 447: 653-665 (2004).
6. Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S. and Abe, T.:The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet.,19: 171-179 (2004).
7. Schinkel, A. H. and Jonker, J. W.: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 55: 3-29 (2003).
8. Leslie, E. M., Deeley, R. G. and Cole, S. P.: Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 204:216-237 (2005).
9. Borst, P., de Wolf, C. and van de Wetering, K.: Multidrug resistance-associated proteins 3, 4, and 5. Pflügers. Arch., 453:661-673 (2007).
10. Kruh, G. D., Belinsky,M. G., Gallo, J. M. and Lee, K.: Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis. Rev., 26: 5-14 (2007).
11. Kivisto, K. T. and Niemi, M.: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res., 24: 239-247 (2007).
12. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M. and Collins, R.: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med., 359: 789-799 (2008).
13. Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., Brett, C. M. and Giacomini, K. M.: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest., 117: 1422-1431 (2007).
14. Shu, Y., Brown, C., Castro, R. A., Shi, R. J., Lin, E. T., Owen, R. P., Sheardown, S. A., Yue, L., Burchard, E. G., Brett, C. M. and Giacomini, K. M.: Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.Clin. Pharmacol. Ther., 83: 273-280 (2008).
15. Nies, A. T. and Keppler, D.: The apical conjugate efflux pump ABCC2 (MRP2). Pflügers. Arch., 453: 643-659 (2007).
16. Tsuji, A. and Tamai, I.: Carrier-mediated intestinal transport of drugs. Pharm. Res., 13: 963-977 (1996).
17. Inui, K., Masuda, S. and Saito, H.: Cellular and molecular aspects of drug transport in the kidney. Kidney Int., 58:944-958 (2000).
18. Hashida, T., Masuda, S., Uemoto, S., Saito, H., Tanaka, K. and Inui, K.: Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. Pharmacol. Ther., 69: 308-316 (2001).
19. Sakurai, Y., Motohashi, H., Ueo, H., Masuda, S., Saito, H., Okuda, M., Mori, N., Matsuura, M., Doi, T., Fukatsu, A., Ogawa, O. and Inui, K.: Expression levels of renal organic anion transporters(OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm. Res., 21: 61-67 (2004).
20. Sakurai, Y., Motohashi, H., Ogasawara, K., Terada, T., Masuda, S., Katsura, T., Mori, N., Matsuura, M., Doi, T., Fukatsu, A. and Inui, K.: Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm. Res., 22: 2016-2022 (2005).
21. Terada, T., Shimada, Y., Pan, X., Kishimoto, K., Sakurai, T., Doi, R., Onodera, H., Katsura, T., Imamura, M. and Inui, K.: Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochem. Pharmacol., 70: 1756-1763 (2005).
22. Terada, T. and Inui, K.: Gene expression and regulation of drug transporters in the intestine and kidney. Biochem. Pharmacol.,73: 440-449 (2007).
23. Zollner, G., Fickert, P., Zenz, R., Fuchsbichler, A., Stumptner, C., Kenner, L., Ferenci, P., Stauber, R. E., Krejs, G. J., Denk, H.,Zatloukal, K. and Trauner, M.: Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology, 33: 633-646 (2001).
24. Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Marschall, H. U., Zatloukal, K., Denk, H. and Trauner, M.: Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol., 38: 717-727 (2003).
25. Shoda, J., Kano, M., Oda, K., Kamiya, J., Nimura, Y., Suzuki, H., Sugiyama, Y., Miyazaki, H., Todoroki, T., Stengelin, S., Kramer, W.,Matsuzaki, Y. and Tanaka, N.: The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am. J. Gastroenterol., 96:3368-3378 (2001).
26. Motohashi, H., Sakurai, Y., Saito, H., Masuda, S., Urakami, Y., Goto, M., Fukatsu, A., Ogawa, O. and Inui, K.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol., 13: 866-874 (2002).
27. Masuda, S., Terada, T., Yonezawa, A., Tanihara, Y., Kishimoto, K., Katsura, T., Ogawa, O. and Inui, K.: Identification and functional characterization of a new human kidney-specific H＋/organiccation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol., 17: 2127-2135 (2006).
28. Uwai, Y., Masuda, S., Goto, M., Motohashi, H., Saito, H., Okuda, M., Nakamura, E., Ito,N., Ogawa, O. andInui, K.: Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J. Hum. Genet., 49: 40-45 (2004).
29. Aoki, M., Terada, T., Ogasawara, K., Katsura, T., Hatano, E., Ikai, I. and Inui, K.: Impact of regulatory polymorphisms in organicanion transporter genes in the human liver. Pharmacogent.Genomics, 19: 647-656 (2009).
30. Nishimura, M. and Naito, S.: Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet., 20: 452-477 (2005).
31. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.L. and Karlsson, J.: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos., 35: 1333-1340 (2007).
32. Russel, F. G., Koenderink, J. B. and Masereeuw, R.: Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci.,29: 200-207 (2008).
33. Rius, M., Nies, A. T., Hummel-Eisenbeiss, J., Jedlitschky, G. and Keppler, D.: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.Hepatology, 38: 374-384 (2003).
34. Gradhand, U., Lang, T., Schaeffeler, E., Glaeser, H., Tegude, H., Klein, K., Fritz, P., Jedlitschky, G., Kroemer, H. K., Bachmakov, I., Anwald, B., Kerb, R., Zanger, U. M., Eichelbaum, M., Schwab, M. and Fromm, M. F.: Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J., 8: 42-52 (2008).
35. Wagner, M., Fickert, P., Zollner, G., Fuchsbichler, A., Silbert, D., Tsybrovskyy, O., Zatloukal, K., Guo, G. L., Schuetz, J. D., Gonzalez, F. J., Marschall, H. U., Denk, H. and Trauner, M.: Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology,125: 825-838 (2003).
36. Denk, G. U., Soroka, C. J., Takeyama, Y., Chen,W. S., Schuetz, J. D. and Boyer, J. L.: Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J. Hepatol., 40:585-591 (2004).
37. Mennone, A., Soroka, C. J., Cai, S. Y., Harry, K., Adachi, M., Hagey, L., Schuetz, J. D. and Boyer, J. L.: mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology, 43: 1013-1021 (2006).
38. Keitel, V., Burdelski, M., Warskulat, U., Kuhlkamp, T., Keppler, D., Haussinger, D. and Kubitz, R.: Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology, 41: 1160-1172 (2005).
39. Zollner, G., Wagner, M., Fickert, P., Silbert, D., Gumhold, J., Zatloukal, K., Denk, H. and Trauner, M.: Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int., 27: 920-929 (2007).
40. Barnes, S. N., Aleksunes, L. M., Augustine, L., Scheffer, G. L.,Goedken, M. J., Jakowski, A. B., Pruimboom-Brees, I. M., Cherrington, N. J. and Manautou, J. E.: Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab. Dispos., 35: 1963-1969 (2007).
41. Hinoshita, E., Taguchi, K., Inokuchi, A., Uchiumi, T., Kinukawa, N., Shimada, M., Tsuneyoshi, M., Sugimachi, K. and Kuwano, M.: Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. J.Hepatol., 35: 765-773 (2001).
42. +-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab. Dispos., 36:1786-1793 (2008).
43. Seronello, S., Sheikh, M. Y. and Choi, J.: Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free. Radic. Biol. Med., 43: 869-882 (2007).
44. Sheikh, M. Y., Choi, J., Qadri, I., Friedman, J. E. and Sanyal, A. J.: Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology, 47: 2127-2133 (2008).
45. Vee, M. L., Lecureur, V., Stieger, B. and Fardel, O.: Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-a or interleukin-6. Drug Metab. Dispos., 37: 685-693 (2009).
46. Burdette, D., Olivarez, M. and Waris, G.: Activation of transcription factor Nrf2 by hepatitis C virus induces cell survival pathway. J. Gen. Virol., 91: 681-690 (2010) (doi:10.1099/vir.0.014340-0).
47. Maher, J. M., Dieter, M. Z., Aleksunes, L. M., Slitt, A. L., Guo, G., Tanaka, Y., Scheffer, G. L., Chan, J. Y., Manautou, J. E., Chen, Y., Dalton, T. P., Yamamoto, M. and Klaassen, C. D.: Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology, 46: 1597-1610 (2007).